Immunohistochemical study of nuclear factor-κB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers

Journal of Clinical Pathology

Volumn 60, Issue 11, 2007, Pages 1232-1237

  Jenkins, G J S ^a   Mikhail, J ^a   Alhamdani, A ^b   Brown, T H ^b   Caplin, S ^b   Manson, J M ^c   Bowden, R ^d   Toffazal, N ^d   Griffiths, A P ^d   Parry, J M ^a   Baxter, J N ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

^c SINGLETON HOSPITAL   (United Kingdom)

^d ABERTAWE BRO MORGANNWG UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; SYNAPTOTAGMIN I;

ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METAPLASIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CARRIER PROTEINS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; INTERLEUKIN-8; NEOPLASM PROTEINS; NF-KAPPA B; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 36048967287     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.043976     Document Type: Article

References (19)

1. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
2. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-esophageal junction. Lancet 1994;344:1533-6.
3. Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett) esophagus-comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
4. Jankowski JA, Harrison RF, Perry I, et al. Barrett's metaplasia. Lancet 2000;356:2079-85.
5. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84.
6. Jankowski JAZ, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002;122:588-90.
7. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophogastric junction. Gastroenterology 1993;104:510-13.
8. Devesa S, Blot W, Fraumeni J Jr. Changing patterns in the incidences of esophageal and gastric carcinoma in the United States. Cancer 1998;15:2049-53.
9. Lerut T, Coosemans W, De Leyn P, et al. Reflections on three field lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction. Hepatogastroenterology 1999;46:717-25.
10. Jenkins GJS, Doak SH, Parry JM, et al. Barrett's oesophagus: the genetic pathways involved in its progression to adenocarcinoma. Br J Surg 2002;89:824-37.
11. Rayet B, Gelinas C. Aberrant rel/nfκβ genes and activity in human cancer. Oncogene 1999;18:6938-47.
12. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-κB activation in esophageal adenocarcinoma. Relationship to Barrett's metaplasia, survival and response to neoadjuvant chemotherapy. Ann Surg 2004;239:491-500.
13. Jenkins GJS, Harries K, Doak SH, et al. The bile acid deoxycholic acid at neutral pH activates NFKB and causes upregulation of IL-8. Carcinogenesis 2004;25:317-23.
14. Bar Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999;67:12-18.
15. Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002;51:316-22.
16. Konturek PC, NikiforukA, Kania J, et al. Activation of NFKB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and over-expression of cox-2, ppargamma and growth factors. Dig Dis Sci 2004;49:1075-83.
17. O'Riordan JM, AbaelLatif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa B expression along the inflammation- metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005;100:1257-64.
18. Lessard L, Begin LR, Gleave ME, et al. Nuclear localisation of the nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005;93:1019-23.
19. Ladner KJ, Caliguri MA, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss or skeletal muscle gene products. J Biol Chem 2003;278:2294-303.